Context Therapeutics (CNTX) Accounts Payables (2020 - 2026)
Context Therapeutics (CNTX) posted Accounts Payables of $2.5 million for Q1 2026, down 2.65% sequentially from $2.5 million in Q4 2025, and up 146.26% YoY from $1.0 million in Q1 2025.
Context Therapeutics (CNTX) Accounts Payables (2020 - 2026) Analysis & Trends
Context Therapeutics has reported Accounts Payables for 7 years, with the latest figure at $2.5 million in Q1 2026.
- Quarterly Accounts Payables rose 146.26% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (up 146.26% YoY) and the FY2025 annual result came in at $2.5 million, up 74.42% from the prior year.
- Accounts Payables eased to $2.5 million in Q1 2026 per CNTX's latest filing, from $2.5 million in the prior quarter.
- Over five years, Accounts Payables peaked at $2.7 million in Q3 2025 and troughed at $454834.0 in Q1 2022.
- A 5-year average of $1.6 million and a median of $1.5 million in 2024 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2025: Accounts Payables plunged 51.52% in 2022, then soared 291.8% in 2025.
- Over 5 years, Accounts Payables stood at $936330.0 in 2022, then soared by 154.51% to $2.4 million in 2023, then sank by 39.06% to $1.5 million in 2024, then soared by 74.42% to $2.5 million in 2025, then slipped by 2.65% to $2.5 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $2.5 million, $2.5 million, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Context Therapeutics | 48.18 Mn | 48.18 Mn | - | 3.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.29 Mn |
| Mar 31, 2026 | 2.47 Mn |
| Dec 31, 2025 | 2.53 Mn |
| Sep 30, 2025 | 2.72 Mn |
| Jun 30, 2025 | 2.40 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 1.45 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 611,513.00 |
| Mar 31, 2024 | 2.05 Mn |
| Dec 31, 2023 | 2.38 Mn |
| Sep 30, 2023 | 1.83 Mn |
| Jun 30, 2023 | 1.19 Mn |
| Mar 31, 2023 | 1.21 Mn |
| Dec 31, 2022 | 936,330.00 |
| Sep 30, 2022 | 1.49 Mn |
| Jun 30, 2022 | 945,462.00 |
| Mar 31, 2022 | 454,834.00 |
| Dec 31, 2021 | 1.83 Mn |
| Sep 30, 2021 | 3.08 Mn |